About 50% of all metastatic colorectal tumors harbor RAS mutations¹. The frequency of NRAS mutations in exons 2, 3 and 4 is around 5%1. The frequency of BRAF mutations in mCRC is 8%¹.
The Idylla™ NRAS-BRAF-EGFR S492R Mutation Assay allows detection of NRAS, BRAF and EGFR 492 mutations directly from formalin-fixed paraffin-embedded (FFPE) tissue sections in approx. 2 hours with less than 2 minutes hands-on time.
- Directly from FFPE tissue sections
- Approx. 2 hours total turnaround time from sample to result
- Less than 2 minutes hands-on time
- Detection of 25 relevant mutations: 8 NRAS mutations in codons 12 and 13 (exon 2), 6 NRAS mutations in codons 59 and 61 (exon 3), 4 NRAS mutations in codons 117 and 146 (exon 4), 5 BRAF mutations in codon 600 (exon 15) and 2 EGFR mutations in codon 492 (exon 12)
- Highly standardized
- An average sensitivity of 1-5% based on research data
- Contamination-controlled design
¹ Jean-Yves Douillard, M.D., Ph.D., Kelly S. Oliner, Ph.D., Salvatore Siena, M.D., et al. Panitumumab–FOLFOX4 Treatment and
RAS Mutations in Colorectal Cancer. N Engl J Med 2013;369:1023-34.